Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
PROCEPT BioRoboticsMEX:PRCT 44 EV-to-FCF is -12.32 as of Aug. 11, 2026. GuruFocus rates MEX:PRCT with a GF Score™ of 44/100 and a GF Value™ of MXN1,386.73 (Significantly Undervalued). The stock has 1 warning sign investors should review. Among 412 Medical Devices & Instruments companies, PROCEPT BioRobotics ranks worse than 242718.2% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, PROCEPT BioRobotics's Enterprise Value is MXN18,739 Mil.
PROCEPT BioRobotics's Free Cash Flow for the trailing twelve months (TTM) ended in Jun. 2026 was MXN-1,521 Mil. Therefore, PROCEPT BioRobotics's EV-to-FCF for today is -12.32.
The historical rank and industry rank for PROCEPT BioRobotics's EV-to-FCF or its related term are showing as below:
MEX:PRCT'
s EV-to-FCF Range Over the Past 10 Years
Min: -48.63 Med: -20.55 Max: -0.53
Current: -12.87
During the past 7 years, the highest EV-to-FCF of PROCEPT BioRobotics was -0.53. The lowest was -48.63. And the median was -20.55.
MEX:PRCT's EV-to-FCF is ranked worse than 100% of 412
companies
in the Medical Devices & Instruments industry
Industry Median: 24.855
vs MEX:PRCT: -12.87
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
PROCEPT BioRobotics's PE Ratio (TTM) for today is calculated as:
PROCEPT BioRobotics's share price for today is MXN357.00.
PROCEPT BioRobotics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was MXN-34.719.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
PROCEPT BioRobotics EV-to-FCF Related Terms
PROCEPT BioRobotics EV-to-FCF Historical Data
* Premium members only.
The historical data trend for PROCEPT BioRobotics's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MEX:PRCT vs INMD, LMRI, QDEL: EV-to-FCF Comparison
For the Medical Devices subindustry, PROCEPT BioRobotics's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
PROCEPT BioRobotics EV-to-FCF vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, PROCEPT BioRobotics's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where PROCEPT BioRobotics's EV-to-FCF falls into.
PROCEPT BioRobotics's current Enterprise Value is MXN18,739 Mil.
PROCEPT BioRobotics's Free Cash Flow for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was MXN-1,521 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PROCEPT BioRobotics (MEX:PRCT) has a EV-to-FCF of -12.32 as of Aug. 11, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on PROCEPT BioRobotics and its competitors. According to the industry distribution chart, PROCEPT BioRobotics ranks #999999 out of 412 companies in the Medical Devices & Instruments industry.
Is PROCEPT BioRobotics' EV-to-FCF too high?
PROCEPT BioRobotics' current EV-to-FCF is -12.32. Based on the distribution chart, PROCEPT BioRobotics ranks #999999 out of 412 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, PROCEPT BioRobotics has a GF Score™ of 44/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does PROCEPT BioRobotics' EV-to-FCF compare to INMD and LMRI?
According to the Medical Devices & Instruments industry distribution chart, PROCEPT BioRobotics ranks #999999 out of 412 companies for EV-to-FCF. This places PROCEPT BioRobotics in the lower half of its industry. The industry median EV-to-FCF is 24.86. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Medical Devices & Instruments company?
The median EV-to-FCF among Medical Devices & Instruments companies is 24.86, based on 412 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on PROCEPT BioRobotics and its competitors. For the Medical Devices & Instruments industry, the median EV-to-FCF is 24.86 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. PROCEPT BioRobotics's current EV-to-FCF is -12.32. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PROCEPT BioRobotics stock overvalued right now?
Based on GuruFocus' analysis, PROCEPT BioRobotics (MEX:PRCT) is currently considered Significantly Undervalued. The stock's GF Value™ is MXN1,386.73, compared to a current price of MXN357.00 — trading 74.3% below its estimated fair value. The current EV-to-FCF is -12.32. PROCEPT BioRobotics' overall GF Score™ is 44/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For PROCEPT BioRobotics (MEX:PRCT), the current EV-to-FCF is -12.32 as of Aug. 11, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is PROCEPT BioRobotics (MEX:PRCT) Overvalued in 2026?
Based on GuruFocus' analysis, PROCEPT BioRobotics stock appears to be undervalued.
The current stock price of MXN357.00 is trading 74.3% below its estimated GF Value™ of MXN1,386.73.
GuruFocus considers PROCEPT BioRobotics to be Significantly Undervalued.
Key valuation signals for MEX:PRCT:
EV-to-FCF: -12.32
GF Value™: MXN1,386.73 vs. price of MXN357.00 (74.3% below fair value)
No single metric tells the full story. See the MEX:PRCT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
PROCEPT BioRobotics Corp is a surgical robotics company focused on advancing patient care by developing transformative solutions in urology. The company develops, manufactures, and sells the AquaBeam Robotic System and HYDROS Robotic System, image-guided, surgical robotic systems for use in minimally invasive urologic surgery, with an initial focus on treating benign prostatic hyperplasia, or BPH. Geographically, the company generates a majority of its revenue from the United States and also has a presence in markets outside the U.S.
44GF Score
Get the complete analysis for MEX:PRCT
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:PRCT has been successfully added to your 
